Ilyang Pharmaceutical Co.,Ltd

KOSE:A007570 Stock Report

Market Cap: ₩231.7b

Ilyang PharmaceuticalLtd Balance Sheet Health

Financial Health criteria checks 4/6

Ilyang PharmaceuticalLtd has a total shareholder equity of ₩271.4B and total debt of ₩121.7B, which brings its debt-to-equity ratio to 44.8%. Its total assets and total liabilities are ₩533.6B and ₩262.2B respectively. Ilyang PharmaceuticalLtd's EBIT is ₩20.6B making its interest coverage ratio 7.6. It has cash and short-term investments of ₩26.9B.

Key information

44.8%

Debt to equity ratio

₩121.68b

Debt

Interest coverage ratio7.6x
Cash₩26.86b
Equity₩271.37b
Total liabilities₩262.25b
Total assets₩533.61b

Recent financial health updates

Here's Why Ilyang PharmaceuticalLtd (KRX:007570) Has A Meaningful Debt Burden

Jan 03
Here's Why Ilyang PharmaceuticalLtd (KRX:007570) Has A Meaningful Debt Burden

Is Ilyang PharmaceuticalLtd (KRX:007570) A Risky Investment?

Apr 04
Is Ilyang PharmaceuticalLtd (KRX:007570) A Risky Investment?

Here's Why Ilyang PharmaceuticalLtd (KRX:007570) Can Manage Its Debt Responsibly

Dec 24
Here's Why Ilyang PharmaceuticalLtd (KRX:007570) Can Manage Its Debt Responsibly

Recent updates

Ilyang Pharmaceutical Co.,Ltd's (KRX:007570) 28% Price Boost Is Out Of Tune With Revenues

Jan 06
Ilyang Pharmaceutical Co.,Ltd's (KRX:007570) 28% Price Boost Is Out Of Tune With Revenues

Here's Why Ilyang PharmaceuticalLtd (KRX:007570) Has A Meaningful Debt Burden

Jan 03
Here's Why Ilyang PharmaceuticalLtd (KRX:007570) Has A Meaningful Debt Burden

Is Ilyang PharmaceuticalLtd (KRX:007570) A Risky Investment?

Apr 04
Is Ilyang PharmaceuticalLtd (KRX:007570) A Risky Investment?

Should You Be Adding Ilyang PharmaceuticalLtd (KRX:007570) To Your Watchlist Today?

Mar 14
Should You Be Adding Ilyang PharmaceuticalLtd (KRX:007570) To Your Watchlist Today?

Ilyang Pharmaceutical Co.,Ltd (KRX:007570) Shares May Have Slumped 36% But Getting In Cheap Is Still Unlikely

Mar 14
Ilyang Pharmaceutical Co.,Ltd (KRX:007570) Shares May Have Slumped 36% But Getting In Cheap Is Still Unlikely

Declining Stock and Decent Financials: Is The Market Wrong About Ilyang Pharmaceutical Co.,Ltd (KRX:007570)?

Feb 22
Declining Stock and Decent Financials: Is The Market Wrong About Ilyang Pharmaceutical Co.,Ltd (KRX:007570)?

Did Business Growth Power Ilyang PharmaceuticalLtd's (KRX:007570) Share Price Gain of 159%?

Feb 01
Did Business Growth Power Ilyang PharmaceuticalLtd's (KRX:007570) Share Price Gain of 159%?

Is Ilyang Pharmaceutical Co.,Ltd's (KRX:007570) Shareholder Ownership Skewed Towards Insiders?

Jan 11
Is Ilyang Pharmaceutical Co.,Ltd's (KRX:007570) Shareholder Ownership Skewed Towards Insiders?

Here's Why Ilyang PharmaceuticalLtd (KRX:007570) Can Manage Its Debt Responsibly

Dec 24
Here's Why Ilyang PharmaceuticalLtd (KRX:007570) Can Manage Its Debt Responsibly

A Look At The Intrinsic Value Of Ilyang Pharmaceutical Co.,Ltd (KRX:007570)

Dec 06
A Look At The Intrinsic Value Of Ilyang Pharmaceutical Co.,Ltd (KRX:007570)

Ilyang Pharmaceutical Co.,Ltd (KRX:007570) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Nov 18
Ilyang Pharmaceutical Co.,Ltd (KRX:007570) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Financial Position Analysis

Short Term Liabilities: A007570's short term assets (₩206.1B) do not cover its short term liabilities (₩230.5B).

Long Term Liabilities: A007570's short term assets (₩206.1B) exceed its long term liabilities (₩31.8B).

Debt to Equity History and Analysis

Debt Level: A007570's net debt to equity ratio (34.9%) is considered satisfactory.

Reducing Debt: A007570's debt to equity ratio has reduced from 61.9% to 44.8% over the past 5 years.

Debt Coverage: A007570's debt is not well covered by operating cash flow (1.9%).

Interest Coverage: A007570's interest payments on its debt are well covered by EBIT (7.6x coverage).

Balance Sheet

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/07 00:03
End of Day Share Price 2025/01/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ilyang Pharmaceutical Co.,Ltd is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hyung Soo KimCape Investment & Securities Co., Ltd.
Jae Hoon ShinLS Securities Co., Ltd.
Jaechul ParkMirae Asset Securities Co., Ltd. (Pre-Merger)